Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Trial of AdCOVID

Trial Profile

A Phase 1 Clinical Trial of AdCOVID

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2020

At a glance

  • Drugs Coronavirus vaccine-Altimmune (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Altimmune
  • Most Recent Events

    • 11 Aug 2020 According to an Altimmune media release, data from that study, including validation of the compounds weight loss and liver fat-reducing effects, is expected to read out in the spring of 2021.
    • 29 Jun 2020 According to an Altimmune media release, the Company intends to initiate manufacturing of AdCOVID in July with the Phase 1 clinical trial expected to begin in Q4 of this year.
    • 13 May 2020 According to an Altimmune media release, the company expects to initiate this study early as Q4 of this year.

Trial Overview

Purpose

This phase I study will evaluate intranasal AdCOVID (coronavirus vaccine) for COVID-19.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Sponsors Altimmune
  • Affiliations Altimmune

Trial Dates

  • Initiation Dates

    Planned : 01 Oct 2020

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
Coronavirus vaccine-AltimmunePrimary Drug Nasal
-

Coronavirus-vaccine-Altimmune

Intranasal

Trial Centres

Centres

Centre Name Location Trial Centre Country
Altimmune, Inc.
-
-

Trial History

Event Date Event Type Comment
11 Aug 2020 Other trial event According to an Altimmune media release, data from that study, including validation of the compounds weight loss and liver fat-reducing effects, is expected to read out in the spring of 2021. Updated 17 Aug 2020
29 Jun 2020 Other trial event According to an Altimmune media release, the Company intends to initiate manufacturing of AdCOVID in July with the Phase 1 clinical trial expected to begin in Q4 of this year. Updated 06 Jul 2020
13 May 2020 Other trial event According to an Altimmune media release, the company expects to initiate this study early as Q4 of this year. Updated 18 May 2020
31 Mar 2020 New trial record New trial record Updated 31 Mar 2020
27 Mar 2020 Other trial event According to an Altimmune media release, the company expects to initiate this study early as Q3 of this year. Updated 31 Mar 2020

References

  1. Altimmune. Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update. Media-Rel 2020;.

    Media Release
  2. Altimmune. Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update. Media-Rel 2020;.

    Media Release
  3. Altimmune. Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID(Tm) in Outpatients with Early COVID-19. Media-Rel 2020;.

    Media Release
  4. Altimmune. Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update. Media-Rel 2020;.

    Media Release
Back to top